Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymphoma, it was approved for the treatment of another type of lymphoma (mantle cell), by the Food and Drug Administration (FDA). Acalabrutinib acts similar to another cancer drug called ibrutinib. lbrutinib was tested in several research trials for the management of CNS lymphomas, and the results were promising. Acalabrutinib and ibrutinib attack a similar target found in CNS lymphoma. Acalabrutinib may do a better job in attacking this target than ibrutinib. The study doctors will be looking to see if acalabrutinib can shrink cancer cells. The participants will be given acalabrutinib and isavuconazole, because isavuconazole helps in preventing fungal infections that may occur during acalabrutinib treatment.


Clinical Trial Description

This multicenter open-label, single-arm, pilot study explores a safe and effective treatment for relapsed central nervous system lymphoma. The study investigates the antitumor effects and safety of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Types of SCNSL included in the study are: Diffuse large B-cell lymphoma, mantle cell lymphoma, plasmablastic lymphoma, and lymphoplasmacytic lymphoma. Up to 16 subjects will be enrolled to attain a total of 15 evaluable subjects. Duration of Therapy: Treatment with acalabrutinib and isavuconazole will continue unless - Disease progression - Inter-current illness that prevents further administration of treatment - Unacceptable adverse event(s) - Pregnancy - Subject decides to withdraw from study treatment, - General or specific changes in the subject's condition render the subject unacceptable for further treatment in the judgment of the investigator, or - Subject is lost to follow up Duration of Follow-up All subjects will be followed for survival for 5 years or until death, whichever occurs first. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04548648
Study type Interventional
Source UNC Lineberger Comprehensive Cancer Center
Contact Lynn Ruffin
Phone 9193081724
Email Lynn_ruffin@med.unc.edu
Status Recruiting
Phase Phase 2
Start date October 15, 2020
Completion date February 22, 2033

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516655 - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients Phase 2
Recruiting NCT05054426 - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Phase 3
Recruiting NCT02623010 - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Phase 2
Active, not recruiting NCT00293475 - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 1/Phase 2
Completed NCT03342586 - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT01011920 - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00967200 - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors N/A
Recruiting NCT03684980 - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Early Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04938297 - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma Phase 2
Recruiting NCT04792489 - DALY II USA/ MB-CART2019.1 for DLBCL Phase 2
Completed NCT01458730 - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00153530 - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Phase 4
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT05816746 - Decitabine and Anti-PD-1 in R/R DLBCL Phase 2
Recruiting NCT06031194 - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting NCT03962127 - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Completed NCT03690895 - Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
Recruiting NCT05114330 - Secondary Central Nervous System Lymphoma Registry - Charité